Lead Product(s): HMBD-002
Therapeutic Area: Oncology
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Hummingbird Bioscience
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement February 20, 2020
Pre-clinical studies have shown that HMBD-002 can strongly inhibit tumor growth, both as a monotherapy and even more potently when combined with anti-PD(L)1 treatment.